Anniina Färkkilä

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial”.

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30180-7

N/A

5.1DataRank · unranked

233 citations

Su-Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer, L. Austin Doyle +19 more

Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0818

N/A

0DataRank · unranked

139 citations

Shuang Zhang, Simge Yucel, Heiko Horn, Sean G. Smith, Ferenc Reinhardt +18 more

MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia

Cell stem cell(2020)10.1016/j.stem.2020.09.004

N/A

0DataRank · unranked

65 citations

Kaiyang Zhang, Anniina Färkkilä, Jessica Filiatrault, Chunyu Yang, Martha Velázquez +20 more

Inhibition of TGFβ1 and TGFβ3 promotes hematopoiesis in Fanconi anemia

Experimental Hematology(2020)10.1016/j.exphem.2020.11.002

N/A

0DataRank · unranked

23 citations

Chunyu Yang, Elissa Furutani, Benilde García‐de Teresa, Martha Velázquez, Jessica Filiatrault +16 more

Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.05.23.111658

N/A

0DataRank · unranked

17 citations

Camille Gelot, Constantia Pantelidou, Adam Y. Li, Hatice Yücel, Rachel E. Davis +9 more

Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation

Cancer Cell(2021)10.1016/j.ccell.2021.10.008

N/A

0DataRank · unranked

197 citations

Riccardo Turrini, Aspram Minasyan, David Barras, Isaac Crespo, Alizée J Grimm +31 more

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

Nature Communications(2021)10.1038/s41467-021-25904-w

N/A

0DataRank · unranked

69 citations

Alexandre André Balieiro Anastácio da Costa, D. Gulhan, Elizabeth K. Lee, Su-Chun Cheng, Andrea E. Wahner Hendrickson +14 more

Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1 -Deficient Cells

Cancer Research(2021)10.1158/0008-5472.can-20-2912

N/A

0DataRank · unranked

38 citations

Alfredo Rodríguez, Jaana Oikkonen, D. Gulhan, Huy Nguyen, Julieta Domínguez +13 more

Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer

Nature Communications(2022)10.1038/s41467-022-28389-3

N/A

0DataRank · unranked

122 citations

Nuppu Lyytikäinen, Julia Casado, Ella Anttila, Angéla Szabó, U.-M. Haltia +12 more

Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer

Cancer Discovery(2022)10.1158/2159-8290.cd-21-1181

N/A

0DataRank · unranked

61 citations

Tito A. Sandoval, Sung‐Min Hwang, Eun Sil Park, Paolo Giovanelli, Deepika Awasthi +16 more

910 STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0910

N/A

0DataRank · unranked

5 citations

Qiwei Wang, Antons Martincuks, Michael Kearns, Tao Jiang, Ziying Lin +12 more

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-005627

N/A

0DataRank · unranked

93 citations

Qiwei Wang, Antons Martincuks, Michael J. Kearns, Tao Jiang, Ziying Lin +13 more

Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5512

N/A

0DataRank · unranked

6 citations

Elizabeth Katherine Lee, Su–Chun Cheng, Alexandre André Balieiro Anastácio da Costa, Andrea E. Wahner Hendrickson, D. Gulhan +14 more

Data from Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells

(2023)10.1158/0008-5472.c.6512719.v1

N/A

0DataRank · unranked

0 citations

Alfredo E. Rodríguez, Jaana Oikkonen, D. Gulhan, Huy Nguyen, J. Domı́nguez +13 more

Data from Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer

(2023)10.1158/2159-8290.c.6549535

N/A

0DataRank · unranked

0 citations

Tito A. Sandoval, Sung‐Min Hwang, Eun Sil Park, Paolo Giovanelli, Deepika Awasthi +16 more